{
    "clinical_study": {
        "@rank": "19943", 
        "arm_group": [
            {
                "arm_group_label": "Zagreb2-1-1", 
                "arm_group_type": "Experimental", 
                "description": "Injection on day 0\u30017\u300121"
            }, 
            {
                "arm_group_label": "Essen", 
                "arm_group_type": "Active Comparator", 
                "description": "Injection on day 0\u30013\u30017\u300114\u300128"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study was to achieve the post-marketing safety and immunogenicity\n      research of Speeda\u00ae rabies vaccine for human use from Chengda Bio"
        }, 
        "brief_title": "The Post-Marketing Safety and Immunogenicity Research of Speeda\u00ae Rabies Vaccine for Human Use", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Rabies Vaccine Allergy", 
            "Vaccination Adverse Event", 
            "Anti-D Antibodies"
        ], 
        "condition_browse": {
            "mesh_term": "Rabies"
        }, 
        "detailed_description": {
            "textblock": "The aim of the research is to compare the two immune procedures. The investigators plan to\n      enroll 10500 participants signed the informed consent who separately inject by Zagreb or\n      Essen procedure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Parent/legal acceptable representatives of children or the adult participants are\n             willing and able to understand the protocol requirements and provide informed consent\n             signed\n\n          -  Participant is considered to be in good health including the body and mental status\n             on the basis of reported medical history and limited physical examination and live in\n             local \u2265 12 months\n\n          -  Participant body temperature \u2264 37.0\u2103\n\n          -  Participant without preventive inoculation of rabies vaccine(only limited in\n             immunogenicity subgroup)\n\n        Exclusion Criteria:\n\n          -  Three-level exposure\n\n          -  Known allergy to any constituent of the vaccine\n\n          -  Reported the history of allergies, convulsions, epilepsy, mental illness and brain\n             disease and clear serious systemic reaction\n\n          -  Known bleeding disorder or suspected impairment of immunologic function, or receipt\n             of immunosuppressive therapy or immunoglobulin since birth\n\n          -  Participation in any other interventional clinical trial\n\n          -  An acute illness with or without fever (temperature \uff1e 37.0\u2103) in the latest week\n             preceding enrollment in the trial\n\n          -  Inoculated other vaccines, immunoglobulin or investigational drugs within 4 weeks\n             prior to participation in the study\n\n          -  Reported clearly the infection of the upper respiratory tract with 6 months Clinical\n             Manifestation of Metabolic, blood system, lungs, heart, the gastrointestinal tract,\n             nervous system, kidneys, urinary system, endocrine, liver disease or malignant tumor\n\n          -  Any condition which, in the opinion of the investigator, would pose a health risk to\n             the subject or interfere with the vaccine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "10500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821911", 
            "org_study_id": "BJCDPC-5"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Zagreb2-1-1", 
                    "Essen"
                ], 
                "description": "Injection on day 0\u30017\u300121", 
                "intervention_name": "Zagreb2-1-1", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Zagreb2-1-1", 
                    "Essen"
                ], 
                "description": "Injection on day 0\u30013\u30017\u300114\u300128", 
                "intervention_name": "Essen", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Zhaoqing", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Guangdong Centers for Disease Control and Prevention"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei"
                    }, 
                    "name": "Wuhan Centers for Disease Control and Prevention"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Beijing Chaoyang District Centers for Disease Control and Prevention"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 4 Study of Speeda\u00ae Rabies Vaccine for Human Use", 
        "overall_official": {
            "affiliation": "Beijing Chaoyang District Centers for Disease Control and Prevention", 
            "last_name": "Nianmin Shi", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence Rate of Adverse Events of the rabies vaccine each injection", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821911"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Antibody titre of the subject on  0\u30017\u300114\u300142\u3001180\u3001365", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Beijing Center for Disease Control and Prevention", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Center for Disease Control and Prevention", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}